Organogel mediated co-delivery of nisin and 5-fluorouracil : a synergistic approach against skin cancer
AIM: The present study aimed to develop topical combinatorial therapy of nisin and 5-fluorouracil in a single nanosized formulation against skin cancer.
METHODS: Nisin and 5-fluorouracil were encapsulated in an organogel system (NF-OG) and investigated for morphology, physicochemical properties, cytotoxicity, encapsulation and release. NF-OG was evaluated against DMBA/TPA murine skin cancer in terms of tumour statistics, histoarchitecture, TUNEL and M1/M2 macrophages.
RESULTS: The optimised NF-OG formulation exhibited particle size of 185.1 ± 11.24 nm, zeta potential of -7.93 ± 0.60 mV, offered substantial drug loading and temporal release. NF-OG therapy led to improved cytotoxicity of nisin and 5-FU against B16-F10 cells, significant decrease in tumour volume (84.983 mm3) in treated group as compared to untreated group (490.482 mm3) accompanied by restoration of histoarchitecture and repolarization of macrophages.
CONCLUSION: The study yielded a promising delivery system exhibiting potent anticancer activity and forms the bases for further applications in clinical settings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Journal of microencapsulation - 39(2022), 7-8 vom: 06. Nov., Seite 609-625 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaur, Jasleen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1414-45-5 |
|---|
| Anmerkungen: |
Date Completed 13.01.2023 Date Revised 13.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/02652048.2022.2149871 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349853371 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349853371 | ||
| 003 | DE-627 | ||
| 005 | 20231226043623.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/02652048.2022.2149871 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1166.xml |
| 035 | |a (DE-627)NLM349853371 | ||
| 035 | |a (NLM)36472891 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kaur, Jasleen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Organogel mediated co-delivery of nisin and 5-fluorouracil |b a synergistic approach against skin cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.01.2023 | ||
| 500 | |a Date Revised 13.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: The present study aimed to develop topical combinatorial therapy of nisin and 5-fluorouracil in a single nanosized formulation against skin cancer | ||
| 520 | |a METHODS: Nisin and 5-fluorouracil were encapsulated in an organogel system (NF-OG) and investigated for morphology, physicochemical properties, cytotoxicity, encapsulation and release. NF-OG was evaluated against DMBA/TPA murine skin cancer in terms of tumour statistics, histoarchitecture, TUNEL and M1/M2 macrophages | ||
| 520 | |a RESULTS: The optimised NF-OG formulation exhibited particle size of 185.1 ± 11.24 nm, zeta potential of -7.93 ± 0.60 mV, offered substantial drug loading and temporal release. NF-OG therapy led to improved cytotoxicity of nisin and 5-FU against B16-F10 cells, significant decrease in tumour volume (84.983 mm3) in treated group as compared to untreated group (490.482 mm3) accompanied by restoration of histoarchitecture and repolarization of macrophages | ||
| 520 | |a CONCLUSION: The study yielded a promising delivery system exhibiting potent anticancer activity and forms the bases for further applications in clinical settings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anticancer peptides; nisin; 5-fluorouracil; drug delivery; skin cancer | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 650 | 7 | |a Nisin |2 NLM | |
| 650 | 7 | |a 1414-45-5 |2 NLM | |
| 650 | 7 | |a Antimetabolites, Antineoplastic |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 700 | 1 | |a Raza, Kaisar |e verfasserin |4 aut | |
| 700 | 1 | |a Preet, Simran |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microencapsulation |d 1989 |g 39(2022), 7-8 vom: 06. Nov., Seite 609-625 |w (DE-627)NLM013098217 |x 1464-5246 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2022 |g number:7-8 |g day:06 |g month:11 |g pages:609-625 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/02652048.2022.2149871 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2022 |e 7-8 |b 06 |c 11 |h 609-625 | ||